{"success":true,"data":{"pressRelease":{"id":"167139","rtpr_id":"nGNX32k388-20261013","ticker":"GMAB","exchange":"NASDAQ","all_tickers":["GMAB"],"title":"Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026","author":"Globe Newswire","published_at":"2026-10-13T10:22:15.978Z","article_body":"Company Announcement\n* Net sales of DARZALEX(®) in the third quarter of 2026 totaled USD 4,239\nmillion\n* Genmab receives royalties on worldwide net sales from Johnson & Johnson\n(J&J, legal entity Janssen Biotech, Inc.)\nCOPENHAGEN, Denmark; October 13, 2026 – Genmab A/S\n(https://www.globenewswire.com/Tracker?data=CkKzDjUTEBJ8xAN8VVvK9fkhU18KJZK2Spe4j7EyLu3DzTTeP-Nys0OOCDecreDUYk8a7WwRJpo8rd5axyAlcg==)\n(Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX\n(daratumumab), including sales of the subcutaneous (SC) product (daratumumab\nand hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO(® )in the\nU.S.), as reported by J&J were USD 4,239 million in the third quarter of 2026.\nNet trade sales were USD 2,528 million in the U.S. and USD 1,711 million in\nthe rest of the world. Genmab receives royalties on the worldwide net sales of\nDARZALEX, both the intravenous and SC products, under the exclusive worldwide\nlicense to J&J to develop, manufacture and commercialize daratumumab.  \n\nAbout Genmab \nGenmab is an international biotechnology company dedicated to improving the\nlives of people with cancer and other serious diseases through innovative\nantibody medicines. For over 25 years, its passionate, innovative and\ncollaborative team has advanced a broad range of antibody-based therapeutic\nformats, including bispecific antibodies, antibody-drug conjugates (ADCs),\nimmune-modulating antibodies and other next-generation modalities. Genmab’s\nscience powers eight approved antibody medicines, and the company is advancing\na strong late-stage clinical pipeline, including wholly owned programs, with\nthe goal of delivering transformative medicines to patients.\n\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with\ninternational presence across North America, Europe and Asia Pacific. For\nmore information, please visit Genmab.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=hb_jM5Jr7rFYYIJ5eSuLBNO2V4XuGEz_b6rzm6oVett_Sp0EjN8V4anR8fegu2JztAHAeLFmukvz_SSgPhIMSMIgWsP8iNki-SQE6B3QztMqouvKH7Lhy8QZWi4jU6m9d-wb2T7meKx0-OEcbP6dCXoXvUt_QbJ4nHoWj2_ObvU2eMFOaytNyhApWi6Dxn-eFndTsy3z4XWmhDMX3aRGe8kS-oBEkjnWXha7awd3HXmmgdmmOrJiqPp7pEYMQStz), X\n(https://www.globenewswire.com/Tracker?data=wabCjibkm30f0gnxaXxhAtMmoNcrJnWEr5O4bh2hFC8-rZBVI54mOgDmPKXFjBU7cz1s_VjddkFVC4lRaz1ZkTSC3A1e3KGm98eKgoin8sIhsabj1s8FVpMBfItLWr0RrTiPp2YsfQLS4TiV64eJh0qXFIhd2ZFQvnTN2ADGW2R7kZTo84xUiLh3JIX1IhymCsOqqZdSNNX81wVM3j120qd7qBIMDiCnXLMYMDLKDzQ=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=hk2j473tA9xswsSqMkQsp0lidQbUCnqfr99moqhiOxkbKYI1bqlyYDBxof-7k5KxHBUc06nvj0kL4rk5dtZGjJ39Jx9K6TZTPDcT-3OiIgWE0cgTrQxKtnQBAJCRkUY4) and Instagram\n(https://www.globenewswire.com/Tracker?data=oaRKRma1LS6Mt15dz-IWJhSIDnoZDMxTm1Z9uOcWoIbl64fmBIM7tjrZZ2wQvp4MaQK92rdIfV9ACCrOLWc_D84ZPH2jm5YCbQXF1cnNW4xmBRJgfiXnCHjMhFD7QGQ76VsRvguQDPyKVNohmJp_fw==).\n\nContact:        \nMarisol Peron, Senior Vice President, Global Communications & Corporate\nAffairs\nT: +1 609 524 0065; E: mmp@genmab.com\n\nAndrew Carlsen, Vice President, Head of Investor Relations\nT: +45 3377 9558; E: acn@genmab.com \n\nThis Company Announcement contains forward looking statements. The words\n“believe,” “expect,” “anticipate,” “intend” and “plan” and\nsimilar expressions identify forward looking statements. Actual results or\nperformance may differ materially from any future results or performance\nexpressed or implied by such statements. The important factors that could\ncause our actual results or performance to differ materially include, among\nothers, risks associated with preclinical and clinical development of\nproducts, uncertainties related to the outcome and conduct of clinical trials\nincluding unforeseen safety issues, uncertainties related to product\nmanufacturing, the lack of market acceptance of our products, our inability to\nmanage growth, the competitive environment in relation to our business area\nand markets, our inability to attract and retain suitably qualified personnel,\nthe unenforceability or lack of protection of our patents and proprietary\nrights, our relationships with affiliated entities, changes and developments\nin technology which may render our products or technologies obsolete, and\nother factors. For a further discussion of these risks, please refer to the\nrisk management sections in Genmab’s most recent financial reports, which\nare available on www.genmab.com and the risk factors included in Genmab’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission (SEC), which are available at www.sec.gov.\nGenmab does not undertake any obligation to update or revise forward looking\nstatements in this Company Announcement nor to confirm such statements to\nreflect subsequent events or circumstances after the date made or in relation\nto actual results, unless required by law. \n\nGenmab A/S and/or its subsidiaries own the following trademarks: Genmab(®);\nthe Y-shaped Genmab logo(®); Genmab in combination with the Y-shaped Genmab\nlogo(®); HuMax(®); DuoBody(®); HexaBody(®); DuoHexaBody(®), HexElect(®\n)and KYSO(®). DARZALEX(®) and DARZALEX FASPRO(®) are trademarks of Johnson\n& Johnson.\n\nCompany Announcement no. 42\nCVR no. 2102 3884\nLEI Code 529900MTJPDPE4MHJ122\n\nGenmab A/S\nCarl Jacobsens Vej 30\n2500 Valby\nDenmark\n\nAttachment\n*     131026_CA42_DARZALEX Q3 2026 sales\n(https://ml-eu.globenewswire.com/Resource/Download/921e9da9-d7d7-4002-ae3b-f79d15a7da79)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX32k388-20261013","title":"Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026","author":"Globe Newswire","ticker":"GMAB","created":"2026-10-13T10:22:15.978Z","tickers":["GMAB"],"exchange":"NASDAQ","article_body":"Company Announcement\n* Net sales of DARZALEX(®) in the third quarter of 2026 totaled USD 4,239\nmillion\n* Genmab receives royalties on worldwide net sales from Johnson & Johnson\n(J&J, legal entity Janssen Biotech, Inc.)\nCOPENHAGEN, Denmark; October 13, 2026 – Genmab A/S\n(https://www.globenewswire.com/Tracker?data=CkKzDjUTEBJ8xAN8VVvK9fkhU18KJZK2Spe4j7EyLu3DzTTeP-Nys0OOCDecreDUYk8a7WwRJpo8rd5axyAlcg==)\n(Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX\n(daratumumab), including sales of the subcutaneous (SC) product (daratumumab\nand hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO(® )in the\nU.S.), as reported by J&J were USD 4,239 million in the third quarter of 2026.\nNet trade sales were USD 2,528 million in the U.S. and USD 1,711 million in\nthe rest of the world. Genmab receives royalties on the worldwide net sales of\nDARZALEX, both the intravenous and SC products, under the exclusive worldwide\nlicense to J&J to develop, manufacture and commercialize daratumumab.  \n\nAbout Genmab \nGenmab is an international biotechnology company dedicated to improving the\nlives of people with cancer and other serious diseases through innovative\nantibody medicines. For over 25 years, its passionate, innovative and\ncollaborative team has advanced a broad range of antibody-based therapeutic\nformats, including bispecific antibodies, antibody-drug conjugates (ADCs),\nimmune-modulating antibodies and other next-generation modalities. Genmab’s\nscience powers eight approved antibody medicines, and the company is advancing\na strong late-stage clinical pipeline, including wholly owned programs, with\nthe goal of delivering transformative medicines to patients.\n\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with\ninternational presence across North America, Europe and Asia Pacific. For\nmore information, please visit Genmab.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=hb_jM5Jr7rFYYIJ5eSuLBNO2V4XuGEz_b6rzm6oVett_Sp0EjN8V4anR8fegu2JztAHAeLFmukvz_SSgPhIMSMIgWsP8iNki-SQE6B3QztMqouvKH7Lhy8QZWi4jU6m9d-wb2T7meKx0-OEcbP6dCXoXvUt_QbJ4nHoWj2_ObvU2eMFOaytNyhApWi6Dxn-eFndTsy3z4XWmhDMX3aRGe8kS-oBEkjnWXha7awd3HXmmgdmmOrJiqPp7pEYMQStz), X\n(https://www.globenewswire.com/Tracker?data=wabCjibkm30f0gnxaXxhAtMmoNcrJnWEr5O4bh2hFC8-rZBVI54mOgDmPKXFjBU7cz1s_VjddkFVC4lRaz1ZkTSC3A1e3KGm98eKgoin8sIhsabj1s8FVpMBfItLWr0RrTiPp2YsfQLS4TiV64eJh0qXFIhd2ZFQvnTN2ADGW2R7kZTo84xUiLh3JIX1IhymCsOqqZdSNNX81wVM3j120qd7qBIMDiCnXLMYMDLKDzQ=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=hk2j473tA9xswsSqMkQsp0lidQbUCnqfr99moqhiOxkbKYI1bqlyYDBxof-7k5KxHBUc06nvj0kL4rk5dtZGjJ39Jx9K6TZTPDcT-3OiIgWE0cgTrQxKtnQBAJCRkUY4) and Instagram\n(https://www.globenewswire.com/Tracker?data=oaRKRma1LS6Mt15dz-IWJhSIDnoZDMxTm1Z9uOcWoIbl64fmBIM7tjrZZ2wQvp4MaQK92rdIfV9ACCrOLWc_D84ZPH2jm5YCbQXF1cnNW4xmBRJgfiXnCHjMhFD7QGQ76VsRvguQDPyKVNohmJp_fw==).\n\nContact:        \nMarisol Peron, Senior Vice President, Global Communications & Corporate\nAffairs\nT: +1 609 524 0065; E: mmp@genmab.com\n\nAndrew Carlsen, Vice President, Head of Investor Relations\nT: +45 3377 9558; E: acn@genmab.com \n\nThis Company Announcement contains forward looking statements. The words\n“believe,” “expect,” “anticipate,” “intend” and “plan” and\nsimilar expressions identify forward looking statements. Actual results or\nperformance may differ materially from any future results or performance\nexpressed or implied by such statements. The important factors that could\ncause our actual results or performance to differ materially include, among\nothers, risks associated with preclinical and clinical development of\nproducts, uncertainties related to the outcome and conduct of clinical trials\nincluding unforeseen safety issues, uncertainties related to product\nmanufacturing, the lack of market acceptance of our products, our inability to\nmanage growth, the competitive environment in relation to our business area\nand markets, our inability to attract and retain suitably qualified personnel,\nthe unenforceability or lack of protection of our patents and proprietary\nrights, our relationships with affiliated entities, changes and developments\nin technology which may render our products or technologies obsolete, and\nother factors. For a further discussion of these risks, please refer to the\nrisk management sections in Genmab’s most recent financial reports, which\nare available on www.genmab.com and the risk factors included in Genmab’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission (SEC), which are available at www.sec.gov.\nGenmab does not undertake any obligation to update or revise forward looking\nstatements in this Company Announcement nor to confirm such statements to\nreflect subsequent events or circumstances after the date made or in relation\nto actual results, unless required by law. \n\nGenmab A/S and/or its subsidiaries own the following trademarks: Genmab(®);\nthe Y-shaped Genmab logo(®); Genmab in combination with the Y-shaped Genmab\nlogo(®); HuMax(®); DuoBody(®); HexaBody(®); DuoHexaBody(®), HexElect(®\n)and KYSO(®). DARZALEX(®) and DARZALEX FASPRO(®) are trademarks of Johnson\n& Johnson.\n\nCompany Announcement no. 42\nCVR no. 2102 3884\nLEI Code 529900MTJPDPE4MHJ122\n\nGenmab A/S\nCarl Jacobsens Vej 30\n2500 Valby\nDenmark\n\nAttachment\n*     131026_CA42_DARZALEX Q3 2026 sales\n(https://ml-eu.globenewswire.com/Resource/Download/921e9da9-d7d7-4002-ae3b-f79d15a7da79)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T10:22:16.021972652Z","server_sent_at_ms":1791886936021},"received_at":"2026-10-13T10:22:16.073Z","source_url":null},"analysis":{"id":"155458","press_release_id":"167139","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Genmab announced worldwide net trade sales of DARZALEX totaled USD 4,239 million in the third quarter of 2026, as reported by partner Johnson & Johnson.\n\nSales split into USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world, including the subcutaneous DARZALEX FASPRO product.\n\nGenmab earns royalties on all worldwide DARZALEX sales under its exclusive license to J&J, so the quarter's sales pace directly drives Genmab's royalty revenue.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"DARZALEX tracks above $4B in quarterly sales, a steady royalty tailwind for Genmab ahead of its own earnings."},"keyFigures":{"revenue":"$4,239 million","customDimensions":{"us_net_sales_usd_m":2528,"row_net_sales_usd_m":1711,"darzalex_q3_worldwide_net_sales_usd_m":4239}},"namedEntities":{"people":[{"name":"Marisol Peron","role":"SVP, Global Communications & Corporate Affairs"},{"name":"Andrew Carlsen","role":"VP, Head of Investor Relations"}],"products":["DARZALEX","DARZALEX FASPRO"],"companies":[{"name":"Genmab A/S","ticker":"GMAB","relationship":"filer"},{"name":"Johnson & Johnson","ticker":"JNJ","relationship":"licensee/partner; reports DARZALEX sales and pays royalties to Genmab"},{"name":"Janssen Biotech, Inc.","relationship":"J&J legal entity holding the daratumumab license"}],"dollarAmounts":[{"amount":"USD 4,239 million","context":"worldwide Q3 2026 DARZALEX net trade sales"},{"amount":"USD 2,528 million","context":"U.S. DARZALEX net trade sales"},{"amount":"USD 1,711 million","context":"rest-of-world DARZALEX net trade sales"}]},"materialImpact":{"score":2,"reasoning":"Routine royalty-basis sales disclosure of a partner-reported drug (DARZALEX Q3 net sales of $4,239M). Positive datapoint for Genmab's royalty stream but no earnings, guidance, or new milestones."},"tickerRelevance":{"others":[{"ticker":"JNJ","relevance":"licensee reporting underlying DARZALEX sales; pays royalties to GMAB"}],"primary":"GMAB"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap biotech","eventGravity":"routine partner-reported sales disclosure","issuerAuthored":true,"royaltyDependence":"DARZALEX royalties are a material Genmab revenue driver"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Genmab announced worldwide net trade sales of DARZALEX totaled USD 4,239 million in the third quarter of 2026, as reported by partner Johnson & Johnson.\n\nSales split into USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world, including the subcutaneous DARZALEX FASPRO product.\n\nGenmab earns royalties on all worldwide DARZALEX sales under its exclusive license to J&J, so the quarter's sales pace directly drives Genmab's royalty revenue.","key_figures":{"revenue":"$4,239 million","customDimensions":{"us_net_sales_usd_m":2528,"row_net_sales_usd_m":1711,"darzalex_q3_worldwide_net_sales_usd_m":4239}},"named_entities":{"people":[{"name":"Marisol Peron","role":"SVP, Global Communications & Corporate Affairs"},{"name":"Andrew Carlsen","role":"VP, Head of Investor Relations"}],"products":["DARZALEX","DARZALEX FASPRO"],"companies":[{"name":"Genmab A/S","ticker":"GMAB","relationship":"filer"},{"name":"Johnson & Johnson","ticker":"JNJ","relationship":"licensee/partner; reports DARZALEX sales and pays royalties to Genmab"},{"name":"Janssen Biotech, Inc.","relationship":"J&J legal entity holding the daratumumab license"}],"dollarAmounts":[{"amount":"USD 4,239 million","context":"worldwide Q3 2026 DARZALEX net trade sales"},{"amount":"USD 2,528 million","context":"U.S. DARZALEX net trade sales"},{"amount":"USD 1,711 million","context":"rest-of-world DARZALEX net trade sales"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T10:22:22.220Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"large-cap biotech","eventGravity":"routine partner-reported sales disclosure","issuerAuthored":true,"royaltyDependence":"DARZALEX royalties are a material Genmab revenue driver"}},"durationMs":6131,"modelName":"glm-5.3-flashx"}}